Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03102125 · ClinicalTrials.gov registry record · Phase 4
Allograft Dysfunction in Heart Transplant
A Phase 4 study of Heart Transplant Failure and Rejection, sponsored by Paul Kim.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 376
- Enrollment target
- 1
- Study location
NCT03102125 is a Phase 4 study of Heart Transplant Failure and Rejection that is actively recruiting participants, run by Paul Kim. The registered enrollment target is 376 participants, above the 136-participant average among 5 other Heart Transplant Failure and Rejection trials with a reported enrollment target (176% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03102125, a Phase 4 study of Heart Transplant Failure and Rejection, is actively recruiting participants, sponsored by Paul Kim.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 376 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will evaluate for early evidence of cardiac allograft dysfunction by cardiac MRI and single cell sequencing to determine underlying molecular and macroscopic causes.
Conditions Studied
Interventions
- DRUG Regadenoson
Study Locations (1)
California
- UC San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2025-12-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03102125
The ClinicalTrials.gov registry entry for NCT03102125 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 136-participant average among 5 other Heart Transplant Failure and Rejection trials with a reported enrollment target (176% higher). The listed sponsor is Paul Kim, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Transplant Failure and Rejection appearing as the primary indexed condition, and to 1 intervention - of which Regadenoson is the first listed.
NCT03102125 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03102125 about?
NCT03102125 is a clinical study titled "Allograft Dysfunction in Heart Transplant". The investigators will evaluate for early evidence of cardiac allograft dysfunction by cardiac MRI and single cell sequencing to determine underlying molecular and macroscopic causes.
What is the current status of trial NCT03102125?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 376 participants. The study started on 2019-10-01. Estimated completion is 2025-12-02.
What conditions does trial NCT03102125 study?
This clinical trial studies the following conditions: Heart Transplant Failure and Rejection.
What interventions are being tested in trial NCT03102125?
The interventions under investigation include: Regadenoson (DRUG).
Who is sponsoring clinical trial NCT03102125?
This trial is sponsored by Paul Kim, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03102125 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Transplant Failure and Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
RECRUITING · Phase 2
-
HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection
ACTIVE NOT RECRUITING
-
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy
ACTIVE NOT RECRUITING · NA
-
Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant
ACTIVE NOT RECRUITING · NA
-
Bioelectrical Impedance Spectroscopy in Heart Transplantation: Tracking Post-Transplant Changes in Body Composition and Correlation With Conventional Preoperative Risk Assessment Modalities
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.